6533b7d9fe1ef96bd126c208
RESEARCH PRODUCT
Aspirin and incident depressive symptoms: A longitudinal cohort study over 8 years
Christoph MuellerAndré F. CarvalhoNicola VeroneseStefania MaggiMichele FornaroTrevor ThompsonBrendon StubbsBrendon StubbsBrendon StubbsMarco SolmiAi KoyanagiBrisa Simoes FernandesBrisa Simoes Fernandessubject
Malemedicine.medical_specialtyLongitudinal studyEpidemiologyAspirin; Cohort; Depression; Epidemiology; Psychiatry; Survey; Geriatrics and Gerontology; Psychiatry and Mental Healthaspirin cohort depression epidemiology psychiatry surveyArticle03 medical and health sciences0302 clinical medicine*aspirinFibrinolytic AgentsInternal medicineMedicineHumansLongitudinal Studies*epidemiologySurveyAgedProportional Hazards Models*surveyPsychiatryAspirinDepressive Disorder*cohortAspirinbusiness.industryProportional hazards modelDepressionIncidence (epidemiology)IncidenceHazard ratioAnti-Inflammatory Agents Non-SteroidalCohortMiddle Aged030227 psychiatryPsychiatry and Mental Health*psychiatryCohortPropensity score matchingPhysical therapyRegression AnalysisFemaleGeriatrics and Gerontologybusiness*depression030217 neurology & neurosurgeryFibrinolytic agentmedicine.drugdescription
Objective: Aspirin exhibits anti-atherosclerotic and anti-inflammatory properties—two potential risk factors for depression. The relationship between aspirin use and depression, however, remains unclear. We investigated whether the aspirin use is associated with a decreased incidence of depressive symptoms in a large North American cohort. Methods: Data from the Osteoarthritis Initiative dataset, a multicenter, longitudinal study on community-dwelling adults was analyzed. Aspirin use was defined through self-report in the past 30 days and confirmed by a trained interviewer. Incident depressive symptoms were defined as a score of ≥16 in the 20-item Center for Epidemiologic Studies-Depression scale. Results: A total of 137 participants (mean age 65 y, 55.5% female) were using aspirin at baseline. Compared with 4003 participants not taking aspirin, no differences in Center for Epidemiologic Studies-Depression at baseline were evident (P =.65). After a median follow-up time of 8 years, the incidence of depressive symptoms was similar in those taking aspirin at baseline (43; 95% CI, 3-60) and in aspirin nonusers (38; 95% CI, 36-41) per 1000 y; log-rank test = 0.63). Based on Cox's regression analysis adjusted for 11 potential confounders, aspirin use was not significantly associated with the development of depressive symptoms (hazard ratio = 1.12; 95% CI, 0.78-1.62; P =.54). Adjustment for propensity scores or the use of propensity score matching did not alter the results. Conclusion: Our study found that prescription of aspirin offered no significant protection against incident depressive symptoms. Whether aspirin is beneficial in a subgroup of depression with high levels of inflammation remains to be investigated in future studies. Copyright © 2017 John Wiley & Sons, Ltd.
year | journal | country | edition | language |
---|---|---|---|---|
2017-08-06 |